The monepantel (MPL) treatment naive B cell lymphoma clinical trial program is transitioning from Phase 2 to Phase 3. Finalisation of dosing optimisation is underway, including investigating MPL in combination either with prednisolone or CHOP-based protocols[1]. The trial involves treatment at home with a consultation at the dog’s nearest trial centre, as listed below. Basic Inclusion and Exclusion criteria are also listed below. Trial centre veterinarians will provide greater detail about enrolment and the nature of the trial.

[1] L- asparaginase, vincristine, cyclophosphamide, prednisolone, and doxorubicin